With $38 million in Series B money, Civitas Therapeutics Inc.’s can finish its ongoing, 80-patient Phase IIb trial testing inhaled levodopa (L-dopa) in Parkinson’s disease patients, and get ready for a Phase III trial that would begin in the second half of next year.